drugset / Trial / NCT06767956
Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy
NaSingle-groupOpen-labelTreatment
Summary
In this combined phase I/II, open label, single arm trial to study, the safety and efficacy of combination Golcadomide and nivolumab in patients with non-Hodgkin lymphoma (NHL) who have experienced refractory/residual disease, at or after 30 days of receiving chimeric antigen T-cell (CAR-T) therapy will be studied. A dose escalation phase will be followed by a dose expansion design.
Timeline
- Start
- 2025-06-30
- Primary completion
- 2027-04-30
- Completion
- 2028-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Golcadomide | Other / unclassified | 0.1 mg | Oral |
| Subject | Golcadomide | Other / unclassified | 0.2 mg | Oral |
| Subject | Golcadomide | Other / unclassified | 0.4 mg | Oral |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |